FDA clears Cadence pain drug for review

Cadence Pharmaceuticals' stock shot up on the FDA announcement that the company does not have to conduct any additional studies of Acetavance, an intravenous version of acetaminophen. Cadence expects to submit an NDA in the second quarter of 2009. Release

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.